Incretin Pathway Comparator Kit research kit - MiPeptidos

Incretin Pathway Comparator Kit Research Brief

Free download — literature summary PDF

Literature SummaryHPLC DataPMIDs + CitationsEN + ES

No spam. Unsubscribe anytime.

Analytical proof

Batch purity, right where researchers look for it.

Each included compound carries its own HPLC result, batch reference, and testing date so the research brief is backed by real analytical proof.

Semaglutide

Purity (HPLC)

99.1%

HR-SMGL-2600315

RP-HPLC C18January 21, 2026

Tirzepatide

Purity (HPLC)

99.2%

HR-TRZP-2600315

RP-HPLC C18January 2, 2026

Metabolic ResearchSave 10%

Incretin Pathway Comparator Kit

Pairs the two most visible incretin-pathway compounds in modern published literature

A two-compound incretin comparator built around the STEP and SURPASS research programs.

Semaglutide anchors the single-receptor GLP-1 literature

Tirzepatide extends the comparison into dual GIP/GLP-1 signaling

Useful for studying single- versus dual-incretin trial design

Built around compounds examined in large modern metabolic studies

Research Use Only.

Research Use Only. These kits are intended for laboratory research purposes only. Not for human consumption. Public-page summaries reflect published literature and analytical documentation, not human-use instructions or treatment claims.

Kit Bundle

$280.71

$311.90

Save $31.19 (10% off)

Semaglutide (10mg)

$86.95

Tirzepatide (10mg)

$224.95

CoA Included

HPLC Verified

Same-Day Shipping

Third-Party Tested

Secured Transactions· 256-bit SSL

Crypto

CoA Included

|HPLC Verified

|GMP Compliant

|Third-Party Tested

|Same-Day Shipping

|Batch Tracked

Evidence snapshot

Built from published research, not guesswork.

Every public research kit now leads with the proof: cited studies, PMIDs, tracked signals, and batch-level documentation across each component.

Featured journals

The New England Journal of Medicine

Observation window

16 weeks

Study phases

Tracked endpoints

Publication span

2016-2022

Featured studies

PMIDs on page

Research signals

COAs included

What researchers commonly track

Common measurements, markers, and readouts associated with this research lane in published literature.

Fasting glucoseHbA1c baselineAppetite VASHOMA-IRFasting insulinCaloric intakeBody weightWaist circumference

Compound architecture

What is inside the kit, structurally

Core chemistry details pulled from each included compound so the page feels like a real research profile, not a generic bundle card.

Semaglutide

CAS: 910463-68-2

Semaglutide is a GLP-1 receptor agonist that mimics native GLP-1 to stimulate insulin secretion in a glucose-dependent manner while suppressing glucagon release. The Aib substitution at position 2 confers resistance to DPP-IV enzymatic degradation, and the C18 fatty diacid chain enables high-affinity albumin binding, extending its half-life substantially. It also acts on hypothalamic appetite centers to reduce food intake and delay gastric emptying.

Molecular formula

C187H291N45O59

Molecular weight

4113.64 Da

Sequence

Modified GLP-1(7-37) analog; 31 amino acids with Aib at position 8, Arg at position 34, and a C18 fatty diacid chain via linker at Lys26

Tirzepatide

CAS: 2023788-19-2

Tirzepatide is a dual GIP and GLP-1 receptor agonist that activates both incretin pathways simultaneously. It stimulates insulin secretion, suppresses glucagon in a glucose-dependent manner, and reduces appetite via central and peripheral signaling. The dual receptor engagement provides synergistic metabolic effects beyond GLP-1 agonism alone, including enhanced lipid metabolism and improved insulin sensitivity.

Molecular formula

C225H348N48O68

Molecular weight

4813.45 Da

Sequence

39-amino acid peptide based on GIP sequence with Aib at positions 2 and 13, and a C20 fatty diacid chain conjugated to Lys20 via a linker; C-terminal amidation

Published study parameters

Typical dose ranges, intervals, and administration routes cited in the literature for the compounds in this kit.

Research Protocol Notes

These peptides are typically used one at a time, not simultaneously. Published sequencing protocols begin with Semaglutide to establish baseline, followed by Tirzepatide if a dual-agonist approach is preferred. Published protocols use gradual titration to minimize GI side effects.

Semaglutide

Same day each week

Dose ranges cited

0.25mg → 2.4mg

Intervals cited

Once weekly

Routes cited

Subcutaneous (abdomen or thigh)

Tirzepatide

Same day each week

Dose ranges cited

2.5mg → 15mg

Intervals cited

Once weekly

Routes cited

Subcutaneous (abdomen or thigh)

These are publication-style study parameters summarized from cited literature and investigational designs. They are provided as research context only, not as human-use instructions or recommendations.

Published Research

Featured peer-reviewed papers supporting the compounds and pairing logic in this kit.

The New England Journal of Medicine2021

Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)

Wilding JPH, Batterham RL, Calanna S, et al.

Published data demonstrated 14.9% mean body weight reduction with Semaglutide 2.4 mg weekly vs. 2.4% with placebo over 68 weeks in participants with overweight or energy-balance research.

PMID: 33567185

The New England Journal of Medicine2022

Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)

Jastreboff AM, Aronne LJ, Ahmad NN, et al.

In peer-reviewed research, Tirzepatide at 15 mg weekly demonstrated mean weight reductions of 22.5% at 72 weeks, the largest weight reduction observed with a pharmacological agent in published trial data.

PMID: 35658024

The New England Journal of Medicine2021

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)

Frias JP, Davies MJ, Rosenstock J, et al.

Published head-to-head data demonstrated Tirzepatide superiority over Semaglutide in HbA1c reduction and body weight change, with dual GIP/GLP-1 activation producing enhanced metabolic outcomes.

PMID: 34170647

The New England Journal of Medicine2016

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)

Marso SP, Bain SC, Consoli A, et al.

Literature demonstrates Semaglutide produced a 26% reduction in major adverse cardiovascular events in published trial data, establishing cardiovascular research interest beyond glucose-regulation research.

PMID: 27633186

What researchers commonly track

Common measurements, markers, and readouts associated with this research lane in published literature.

Body weight & BMI — primary outcome in published trials

HbA1c — glycemic control marker (target < 7.0%)

Fasting glucose & insulin — metabolic function markers

Lipid panel (LDL, HDL, triglycerides) — cardiovascular risk

Waist circumference — visceral adiposity surrogate

Appetite VAS (Visual Analog Scale) — satiety assessment

Observed in the literature

A plain-English view of how published study windows, markers, and reported changes tend to unfold across this research lane.

Weeks 1-2Semaglutide · Tirzepatide

Receptor Engagement & Titration Initiation

Fasting glucoseHbA1c baselineAppetite VAS

Published STEP trial data documented initial GLP-1 receptor engagement with appetite modulation observed in the majority of study participants within 7-14 days

In peer-reviewed studies, low-dose titration of Semaglutide (0.25 mg/week) demonstrated early satiety signaling signaling changes without significant GI disturbance in most subjects

Literature demonstrates Tirzepatide's dual GIP/GLP-1 engagement producing complementary incretin effects from the first administered dose in SURPASS trial cohorts

Weeks 3-4Semaglutide · Tirzepatide

Dose Escalation & Metabolic Adaptation

HOMA-IRFasting insulinCaloric intake

Published research observed dose-dependent increases in insulin sensitivity markers following standard titration protocols in both STEP and SURPASS studies

In peer-reviewed studies, GLP-1 receptor activation demonstrated hepatic glucose output modulation, with measurable fasting glucose changes in study cohorts

Literature demonstrates Tirzepatide's GIP receptor co-activation producing enhanced beta-cell responsiveness compared to GLP-1-only approaches in published head-to-head data

Weeks 5-8Semaglutide · Tirzepatide

Active Metabolic Response Phase

Body weightWaist circumferenceVisceral fat (DEXA)

Published STEP 1 trial data documented mean body weight reductions of 5-7% by

In peer-reviewed SURPASS trials, Tirzepatide demonstrated superior glucose-regulation research markers compared to selective GLP-1 agonists at equivalent timepoints

Literature demonstrates measurable changes in visceral adipose tissue distribution as assessed by DEXA in published body composition substudies

Weeks 9-10Semaglutide · Tirzepatide

Cardiovascular & Lipid Marker Changes

LDL-CTriglycerideshs-CRPBlood pressure

Published research observed significant modifications in lipid panel markers including LDL-C, triglycerides, and HDL-C in study populations by this timepoint

In peer-reviewed SELECT trial data, Semaglutide demonstrated cardiovascular outcome research interest independent of weight-change markers in high-risk cohorts

Literature demonstrates reductions in systolic blood pressure of 4-6 mmHg in published SURPASS trial data during this protocol phase

Weeks 11-13Semaglutide · Tirzepatide

Body Composition Remodeling

Lean mass (DEXA)Visceral fat ratioHbA1c

Published STEP trial data documented continued linear weight reduction with mean losses of 10-14% from baseline in the active treatment arm

In peer-reviewed studies, Tirzepatide at highest titrated doses demonstrated up to 22.5% mean weight reduction in the SURPASS-II cohort

Literature demonstrates preferential reduction in visceral adipose tissue with relative preservation of lean mass in published DEXA substudies

Weeks 14-15Semaglutide · Tirzepatide

Metabolic Stabilization

ALTLiver fat (MRI)SF-36 scores

Published research observed plateau effects in body weight trajectory indicating new metabolic setpoint establishment in study cohorts

In peer-reviewed studies, sustained GLP-1/GIP receptor activation demonstrated maintained appetite suppression without significant tachyphylaxis at stable doses

Literature demonstrates improvements in hepatic steatosis markers including ALT normalization and liver fat content reduction in published MRI substudies

Week 16Semaglutide · Tirzepatide

Protocol Endpoint Assessment

Total weight changeHbA1c changeLipid panelHOMA-IR

Published STEP and SURPASS trial endpoints documented comprehensive metabolic improvements across glycemic, lipid, and body composition markers at 16 weeks

In peer-reviewed research, comparative analysis of Semaglutide vs. Tirzepatide provided data on differential receptor-activation outcomes at equivalent timepoints

Literature demonstrates that published trial data supports assessment of continued administration vs. dose modification based on individual response markers

Handling and documentation

Material handling details and batch-level documentation that support clean research workflows.

Water Volume

2 mL bacteriostatic water per 10mg vial

Concentration

5 mg/mL — titrate from 0.25 mg/week according to published protocols

Storage

Refrigerate at 2-8°C after reconstitution. Stable for up to 42 days. Do not freeze.

Why this kit exists

Why these compounds are paired in the literature

Plain-English summaries of the mechanisms and published pairings that make this kit coherent for real research work.

Semaglutide

Semaglutide is a GLP-1 receptor agonist studied extensively in the STEP clinical trials, demonstrating significant effects on appetite-signaling research and metabolic markers (PMID: 33567185).

Tirzepatide

Tirzepatide is a dual GIP/GLP-1 receptor agonist. The SURPASS trials showed it acts on two incretin pathways simultaneously, with notable findings in metabolic research (PMID: 35658024).

Having both compounds available allows researchers to compare single vs. dual-receptor approaches, or study sequential administration patterns.

Included Peptides

What's in This Kit

2 peptides, each with individual COA documentation

Semaglutide

$86.95

glucose-regulation research glucose-regulation research · energy-balance research and metabolic signaling research · cardiometabolic research in diabetic populations

Semaglutide is a GLP-1 receptor agonist that mimics native GLP-1 to stimulate insulin secretion in a glucose-dependent manner while suppressing glucagon release.

10mgGLP-1 / Weight Management

Tirzepatide

$224.95

glucose-regulation research with superior HbA1c reduction · energy-balance research treatment with significant metabolic research outcomes · Dual incretin receptor pharmacology studies

Tirzepatide is a dual GIP and GLP-1 receptor agonist that activates both incretin pathways simultaneously.

10mgGLP-1 / Weight Management

Peptide reading

View All Research Kits →

15% off

Triple Incretin Comparator Kit

Single, dual, and triple agonists — the three compounds studied in STEP, SURPASS, and NEJM Phase 2 trials

3 peptides · Metabolic Research

$407.85$346.67

Save $61.18

12% off

Lipolytic Pathway Study Kit

Three lipolytic mechanisms studied in published research — HGH-fragment activity plus mitochondrial oxidation

3 peptides · Metabolic Research

$134.90$118.71

Save $16.19

12% off

Tissue Repair Research Kit

The two most-cited tissue repair peptides studied together in published literature

2 peptides · Tissue Research

$167.90$147.75

Save $20.15

View All Research Kits →

Start Your Research

Get the complete Incretin Pathway Comparator Kit at $280.71 — save $31.19 versus purchasing each compound separately. Full COA documentation included with every vial.

Choose Your Option Browse All Research Kits